Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection
Year: 2020
Type: article
Study design: Observational Study
Abstract: The interferon-free regimen of simeprevir plus sofosbuvir was recommended by professional guidelines for certain patients with hepatitis C virus (HCV) genotype 1 infection based on the findings of a phase 2 trial. We aimed to evaluate the safety and efficacy of this regimen in clinical practice settings in North America.
DOI: 10.17615/fav0-s715
Authors: Gordon,, Galati,, Vargas,, Sulkowski, Mark S., Lim,, Reddy, K. Rajender, Williams,, Everson,, O'Leary,, Frazier, Lynn M., Darling, Jama M., Muir,, Ramani,, Watts,, Feld,, Trautwein,, Bredfeldt,, Kuo, Alexander, Jacobson, Ira M., Dickson,, Mailliard,, Kuo,, Ben-Ari,, Hassan,, Shiffman,, Sherman,, Sterling,, Harlan,, Sulkowski,, Jacobson,, Di Bisceglie, Adrian M., Pockros,, Nelson,, Kerr,, Fried, Michael W., Fried,, Lim, Joseph K., Di Bisceglie,, Nelson, David R., Brown,, Schiff,, Hinestrosa,, Morelli, Giuseppe, Fenkel,, Reau,, Spivey,, Alam,, Reddy,, Stewart, Thomas G., Levitsky,, Kwo,, Feld, Jordan J., Terrault,, Hawkins,, Pearlman,, Lok,, Brown, Robert S., Chung,, Smith,, Zeuzem,, Morelli,, Manns,, Darling,, Elbeshbeshy,, Afdhal,, Szabo,
Institution: University of North Carolina at Chapel Hill
Language: English
Topic: Hepatitis C virus research
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4297956610